Found: 24
Select item for more details and to access through your institution.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01075-x
- By:
- Publication type:
- Article
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
- Published in:
- Current Osteoporosis Reports, 2017, v. 15, n. 5, p. 499, doi. 10.1007/s11914-017-0399-3
- By:
- Publication type:
- Article
A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.
- Published in:
- 2012
- By:
- Publication type:
- Case Study
Predictive role of sustained imaging MRD negativity assessed by diffusion‐weighted whole‐body MRI in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E230, doi. 10.1002/ajh.26995
- By:
- Publication type:
- Article
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1227, doi. 10.1007/s00277-022-04806-x
- By:
- Publication type:
- Article
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092273
- By:
- Publication type:
- Article
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1735, doi. 10.3390/cancers11111735
- By:
- Publication type:
- Article
Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry
- Published in:
- Cancer Medicine, 2021, v. 10, n. 17, p. 5859, doi. 10.1002/cam4.4136
- By:
- Publication type:
- Article
P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02333-8
- By:
- Publication type:
- Article
OAB-058: Predictive relevance of sustained MRD negativity and of early loss of MRD negativity during maintenance therapy after transplant in newly diagnosed Multiple Myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S36, doi. 10.1016/S2152-2650(21)02130-3
- By:
- Publication type:
- Article
OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S34, doi. 10.1016/S2152-2650(21)02127-3
- By:
- Publication type:
- Article
Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e271, doi. 10.1016/j.clml.2019.09.447
- By:
- Publication type:
- Article
Selecting transplant in the elderly: validation of IMWG frailty score and Revised Myeloma Comorbidity Index compared to clinical judgment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e197, doi. 10.1016/j.clml.2019.09.330
- By:
- Publication type:
- Article
Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e59, doi. 10.1016/j.clml.2017.03.108
- By:
- Publication type:
- Article
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
- Published in:
- 2020
- By:
- Publication type:
- Letter
COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 555, doi. 10.1002/hon.3127
- By:
- Publication type:
- Article
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 759, doi. 10.1002/ajh.25797
- By:
- Publication type:
- Article
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146<sup>+</sup> immunomagnetic enrichment-flow cytometry and soluble E-selectin detection.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 3, p. 319, doi. 10.1002/ajh.22264
- By:
- Publication type:
- Article
Circulating microRNAs and Their Role in Multiple Myeloma.
- Published in:
- Non-Coding RNA, 2019, v. 5, n. 2, p. 1, doi. 10.3390/ncrna5020037
- By:
- Publication type:
- Article
Incidental whole-body MRI evidence of COVID-19 in an asymptomatic patient in a high prevalence region.
- Published in:
- Egyptian Journal of Radiology & Nuclear Medicine, 2020, v. 51, n. 1, p. N.PAG, doi. 10.1186/s43055-020-00288-x
- By:
- Publication type:
- Article
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 23, p. 5069, doi. 10.1002/cncr.33160
- By:
- Publication type:
- Article
Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy.
- Published in:
- EJHaem, 2024, v. 5, n. 3, p. 485, doi. 10.1002/jha2.907
- By:
- Publication type:
- Article